Sargent Bickham Lagudis LLC Bristol Myers Squibb CO Transaction History

Sargent Bickham Lagudis LLC

$1.22 Billion
Q4 2022

A detailed history of Sargent Bickham Lagudis LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 33,843 shares of BMY stock, worth $1.59 Million. This represents 0.2% of its overall portfolio holdings.

Number of Shares

33,843

Previous 34,867 2.94%

Holding current value

$1.59 Million

Previous $2.48 Million 1.82%

% of portfolio

0.2%

Previous 0.22%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 23, 2023	SELL	$68.48 - $81.09 $70,123 - $83,036	-1,024 Reduced 2.94%	33,843 $0
Q3 2022 Oct 27, 2022	SELL	$0.13 - $76.84 $323 - $191,101	-2,487 Reduced 6.66%	34,867 $2.48 Million
Q2 2022 Jul 13, 2022	BUY	$72.62 - $79.98 $183,510 - $202,109	2,527 Added 7.26%	37,354 $2.88 Million
Q1 2022 Apr 27, 2022	SELL	$61.48 - $73.72 $581,846 - $697,686	-9,464 Reduced 21.37%	34,827 $2.54 Million
Q4 2021 Jan 18, 2022	SELL	$53.63 - $62.52 $1.34 Million - $1.56 Million	-25,027 Reduced 36.1%	44,291 $2.76 Million
Q3 2021 Nov 05, 2021	BUY	$59.17 - $69.31 $58,104 - $68,062	982 Added 1.44%	69,318 $4.1 Million
Q2 2021 Jul 19, 2021	BUY	$61.91 - $67.42 $132,487 - $144,278	2,140 Added 3.23%	68,336 $4.57 Million
Q1 2021 May 24, 2021	BUY	$59.34 - $66.74 $257,891 - $290,052	4,346 Added 7.03%	66,196 $4.18 Million
Q4 2020 May 24, 2021	SELL	$57.74 - $65.43 $250,938 - $284,358	-4,346 Reduced 6.57%	61,850 $3.84 Million
Q4 2020 May 24, 2021	BUY	$57.74 - $65.43 $324,845 - $368,109	5,626 Added 9.29%	66,196 $4.18 Million
Q3 2020 Sep 01, 2021	BUY	$57.43 - $63.64 $308,915 - $342,319	5,379 Added 9.75%	60,570 $3.65 Million
Q2 2020 Sep 07, 2021	BUY	$54.82 - $64.09 $2 Million - $2.34 Million	36,563 Added 196.28%	55,191 $3.25 Million
Q1 2020 Sep 07, 2021	SELL	$46.4 - $67.43 $36,516 - $53,067	-787 Reduced 4.05%	18,628 $1.04 Million
Q4 2019 Sep 14, 2021	BUY	$49.21 - $64.19 $58,756 - $76,642	1,194 Added 6.55%	19,415 $1.25 Million
Q3 2019 Sep 14, 2021	BUY	$42.77 - $50.71 $5,346 - $6,338	125 Added 0.69%	18,221 $924,000
Q2 2019 Sep 13, 2021	BUY	$44.62 - $49.34 $133 - $148	3 Added 0.02%	18,096 $821,000
Q1 2019 Sep 13, 2021	SELL	$45.12 - $53.8 $8,617 - $10,275	-191 Reduced 1.04%	18,093 $863,000
Q4 2018 Sep 13, 2021	BUY	$48.76 - $63.23 $13,555 - $17,577	278 Added 1.54%	18,284 $950,000
Q3 2018 Sep 13, 2021	SELL	$55.19 - $62.25 $31,458 - $35,482	-570 Reduced 3.07%	18,006 $1.12 Million
Q2 2018 Sep 13, 2021	SELL	$50.53 - $62.98 $40,171 - $50,069	-795 Reduced 4.1%	18,576 $1.03 Million
Q1 2018 Sep 13, 2021	SELL	$59.92 - $68.98 $19,474 - $22,418	-325 Reduced 1.65%	19,371 $1.23 Million
Q4 2017 Sep 13, 2021	BUY	$59.94 - $65.35 $33,806 - $36,857	564 Added 2.95%	19,696 $1.21 Million
Q3 2017 Sep 13, 2021	BUY	$55.23 - $63.74 $17,452 - $20,141	316 Added 1.68%	19,132 $1.22 Million
Q2 2017 Sep 13, 2021	SELL	N/A	-116 Reduced 0.61%	18,816 $1.05 Million
Q1 2017 Sep 13, 2021	SELL	N/A	-1,484 Reduced 7.27%	18,932 $1.03 Million
Q4 2016 Sep 13, 2021	SELL	N/A	-614 Reduced 2.92%	20,416 $1.19 Million
Q3 2016 Sep 13, 2021	SELL	N/A	-494 Reduced 2.3%	21,030 $1.13 Million
Q2 2016 Sep 07, 2021	SELL	N/A	-361 Reduced 1.65%	21,524 $1.58 Million
Q1 2016 Sep 07, 2021	BUY	N/A	21,885	21,885 $1.4 Million

Others Institutions Holding BMY

# of Institutions

2,806

Shares Held

1.59B

Call Options Held

25.9M

Put Options Held

23.9M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $99.6B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Bickham Lagudis LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Bickham Lagudis LLC with notifications on news.

Account

Sargent Bickham Lagudis LLC Bristol Myers Squibb CO Transaction History